Tone mix
Week by week 52 weeks
Share of Roivant Sciences Ltd. Common Shares's 159 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of Oct 6, 2025 · tone -100Weiss Ratings Reaffirms "Sell (D+)" Rating for Roivant Sciences (NASDAQ:ROIV)-140
- Week of Jan 5, 2026 · tone +99Leerink Raises Price Target as Roivant (ROIV) Accelerates Drug Development Pipeline+83
- Week of Apr 13, 2026 · tone -49Roivant Sciences (ROIV): A Clinical Trial Win Meets a Phase 3 Failure-79
- Week of Sep 8, 2025 · tone +100Roivant Sciences Ltd. (ROIV) Wins Orphan Drug Status in Japan for Mosliciguat+74
- Week of Aug 4, 2025 · tone +99Roivant Sciences Ltd. (ROIV) Stock Analysis: Exploring The 50% Upside Potential For Investors+70
- Week of Oct 20, 2025 · tone -23Wall Street Has a Mixed Opinion on Roivant Sciences Ltd (ROIV)-60
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about Roivant Sciences Ltd. Common Shares in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 5 | +60 |
| Last 30 sessions | 12 | +25 |
| Last 90 sessions | 42 | +29 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Thursday, October 22, 2026
3 headlines, average tone +67: 2 positive, 1 neutral and 0 negative. Showing all 3.
- seekingalpha.com · 1 outletRoivant stock gains on late-stage trial win (ROIV:NASDAQ)Positive
- www.rttnews.com · 1 outletRoivant Sciences Says Brepocitinib Meets Primary Goal In Uveitis Trials; Shares RisePositive
- www.cnbc.com · 1 outletStocks making the biggest moves midday: SPCX, META, SMCI, ROIVNeutral
Show the table · 3 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Roivant stock gains on late-stage trial win (ROIV:NASDAQ) | seekingalpha.com | 1 | Positive |
| Roivant Sciences Says Brepocitinib Meets Primary Goal In Uveitis Trials; Shares Rise | www.rttnews.com | 1 | Positive |
| Stocks making the biggest moves midday: SPCX, META, SMCI, ROIV | www.cnbc.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Wednesday, October 21, 2026
2 headlines, average tone +50: 1 positive, 1 neutral and 0 negative. Showing all 2.
- www.rttnews.com · 1 outletRoivant Sciences Says Brepocitinib Meets Primary Goal In Uveitis Trials; Shares RisePositive
- www.tickerreport.com · 1 outlet26,071 Shares of Roivant Sciences Ltd. $ROIV Purchased by Englebert Financial Advisers LLCNeutral
Show the table · 2 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Roivant Sciences Says Brepocitinib Meets Primary Goal In Uveitis Trials; Shares Rise | www.rttnews.com | 1 | Positive |
| 26,071 Shares of Roivant Sciences Ltd. $ROIV Purchased by Englebert Financial Advisers LLC | www.tickerreport.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Wednesday, October 14, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.dailypolitical.com · 1 outletHead to Head Analysis: Roivant Sciences (NASDAQ:ROIV) vs. Pharming Group (NASDAQ:PHAR)Neutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Head to Head Analysis: Roivant Sciences (NASDAQ:ROIV) vs. Pharming Group (NASDAQ:PHAR) | www.dailypolitical.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Tuesday, October 13, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.themarketsdaily.com · 1 outletAnalyzing Roivant Sciences (NASDAQ:ROIV) and Krystal Biotech (NASDAQ:KRYS)Neutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Analyzing Roivant Sciences (NASDAQ:ROIV) and Krystal Biotech (NASDAQ:KRYS) | www.themarketsdaily.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Monday, October 12, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.themarketsdaily.com · 1 outletReviewing Janux Therapeutics (NASDAQ:JANX) & Roivant Sciences (NASDAQ:ROIV)Neutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Reviewing Janux Therapeutics (NASDAQ:JANX) & Roivant Sciences (NASDAQ:ROIV) | www.themarketsdaily.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about Roivant Sciences Ltd. Common Shares, not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.